ClinicalTrials.gg
CompletedNCT02182141Updated Jul 18, 2014

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 interventional study of BIBF 1120 ES in Multiple Myeloma, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics

02

Conditions studied

  • Multiple Myeloma

Browse trials for

03

In context

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 17 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed diagnosis of multiple myeloma, who did not respond to or after either anthracyclines and pulsed or high-dose therapy and who are currently not eligible for transplant modalities.
  2. Age 18 years or older
  3. of at least six months
  4. Patients have to give written (which must be consistent with ICH-GCP and local legislation)
  5. (ECOG) performance score \<2.
  6. Recovery from all therapy-related toxicities from previous chemo-, immuno- or radiotherapies.

Exclusion criteria

Exclusion Criteria:

  1. History of relevant surgical procedures during the last four weeks prior to treatment with the trial drug, or active ulcers, fractures or injuries with incomplete healing
  2. Active infectious disease
  3. Uncontrolled, severe hypertension
  4. Gastrointestinal disorders anticipated to interfere with the resorption of the study drug
  5. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
  6. less than 1000 / mm³.
  7. count less than 30 000 / mm³
  8. Conjugated greater than 2 mg / dl (> 34 μmol/L, SI unit equivalent)
  9. Aspartate amino transferase () and / or alanine amino transferase (ALT) greater than three times the
  10. Endogenous (ECC) \<20 ml/min
  11. Women and men who are sexually active and unwilling to use a medically acceptable method of
  12. Pregnancy or breastfeeding
  13. Treatment with other drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
  14. Patients unable to comply with the protocol
  15. Active alcohol or drug abuse
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    BIBF 1120

    Drug: BIBF 1120 ES

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    Time frame: Up to 11 months

Secondary outcomes

  1. Incidence and intensity of adverse events according to Common Toxicity Criteria (CTC) associated with increasing doses of BIBF 1120

    Time frame: Up to 11 months

  2. Change from baseline in laboratory parameters

    Time frame: Baseline, up to 11 months

  3. Objective tumor response in surrogate markers

    Time frame: Baseline, up to 11 month

  4. Concentration at 2h (C2,1)

    Time frame: 2 hours after first administration

  5. Change from baseline in cellular protein tyrosine kinase inhibition

    Time frame: Baseline, up to 11 months

  6. Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance score

    Time frame: Baseline, up to 11 months

  7. Change in vital signs

    Time frame: up to 11 months

  8. Change from baseline in electrocardiogram (ECG)

    Time frame: Baseline, up to 11 months

  9. Predose concentration immediately before administration of the Nth dose over the dosing interval τ (Cpre,N)

    Time frame: Up to day 28

  10. Area under the plasma concentration-time curve during the dosing interval τ (24 h) at steady state (AUCτ,ss)

    Time frame: Up to 11 months

  11. Plasma concentration at the time point immediately before dosing at steady state (Cpre,ss)

    Time frame: Up to 11 months

  12. Minimum plasma concentration during the dosing interval τ at steady state (Cmin,ss)

    Time frame: Up to 11 months

  13. Maximum plasma concentration during the dosing interval τ at steady state (Cmax,ss)

    Time frame: Up to 11 months

  14. Time to reach minimum plasma concentration during the dosing interval τ at steady state (tmin,ss)

    Time frame: Up to 11 months

  15. Time to reach maximum plasma concentration during the dosing interval τ at steady state (tmax,ss)

    Time frame: Up to 11 months

  16. Terminal half-life at steady state (t1/2,ss)

    Time frame: Up to 11 months

  17. Apparent plasma clearance at steady state (CL/F,ss)

    Time frame: Up to 11 months

  18. Mean residence time at steady state (MRTpo,ss)

    Time frame: Up to 11 months

  19. Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss)

    Time frame: Up to 11 months

  20. Tumor response assessed according to the European Group for Blood and Marrow Transplantation (EBMT) criteria

    Time frame: Up to 11 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003 and a primary completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 8, 2014
Start
Apr 2003
Primary completionActual
Mar 2005
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02182141
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Apr 2003
Primary completion
Mar 2005
Last update
Jul 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion